Hexarelin + CJC-1295 Peptide Stack
Reviewed by Marcus Hopkin, PhD
Director of Research and Development, Volta Peptides
Written by Volta Peptides Editorial Team · Reviewed September 15, 2026
The Hexarelin and CJC-1295 peptide stack represents a synergistic combination designed to explore the complexities of growth hormone modulation. By leveraging the distinct yet complementary mechanisms of Hexarelin, a potent growth hormone secretagogue, and CJC-1295, an innovative GHRH analogue, researchers aim to enhance the efficacy of growth hormone stimulation. This stack is of particular interest in studies focusing on metabolic health, muscle repair, and potential cardioprotective effects, providing a multifaceted approach to understanding growth hormone dynamics in various physiological contexts.
Stack Overview
This synergistic stack combines Hexarelin (Growth Hormone Secretagogue) and CJC-1295 (Growth Hormone Secretagogue). GHRH analog plus GHRP engage two separate receptors, the standard rationale for pairing the classes
Hexarelin in This Stack
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that binds to the ghrelin receptor (GHS-R1a). It is considered one of the most potent GHRPs available, stimulating greater GH release than GHRH alone. However, it causes relatively rapid receptor desensitization compared to milder GHRPs like ipamorelin, limiting cycle duration to 4-8 weeks. It also has notable cardioprotective properties independent of GH release.
Mechanism: Hexarelin binds to and activates the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus through a triple mechanism: direct stimulation of pituitary somatotroph cells to release stored GH, stimulation of hypothalamic GHRH-releasing neurons, and suppression of somatostatin (the GH-inhibiting hormone). This triple action explains its potent GH pulses. Hexarelin also binds CD36 scavenger receptors on cardiac tissue, providing GH-independent cardioprotective effects including anti-atherosclerotic activity.
CJC-1295 in This Stack
CJC-1295, a synthetic analogue of growth hormone-releasing hormone, was initially developed to address HIV-associated lipodystrophy. This peptide exists in two forms: the DAC (Drug Affinity Complex) variant, which boasts an extended half-life of 5.8 to 8.1 days, and the Mod GRF 1-29 variant, which has a much shorter half-life of approximately 30 minutes. Clinical trials, including two pivotal studies by Teichman et al. in 2006, demonstrated that CJC-1295 can induce dose-dependent increases in growth hormone levels by 2-10 fold and IGF-1 levels by 1.5-3 fold in healthy adults. The DAC version, while effective, may lead to non-physiological GH elevations and associated risks such as receptor desensitization and insulin resistance. In contrast, Mod GRF 1-29 mimics natural pulsatile GH release, thereby promoting safer physiological responses and preserving somatostatin's negative feedback mechanism, which is crucial for maintaining metabolic balance.
Shop Research Peptides
5-Amino-1MQ 10mg
10mg
GHK-Cu 100mg
100mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Tesamorelin vs CJC-1295: Evidence Gaps and Data
No head-to-head trial compares tesamorelin and CJC-1295. Existing evidence is analytical, not clinical, leaving efficacy claims unsupported.
CJC-1295 and Ipamorelin: Human Evidence and Limits
This reference separates what human trials, animal models, and analytical chemistry show about CJC-1295 and ipamorelin from vendor marketing, assessing the strength of the human evidence base and combination-specific safety data.
CJC-1295 and Ipamorelin Dosage: Evidence and Risks
This reference reviews the evidence on CJC-1295 and ipamorelin dosing, distinguishing what controlled studies support from what remains speculative or vendor-derived.
Peptide Tools
Key research references
- Best Peptides for Reproductive Health | Research Guide
- Best Peptides for Anti-Aging | Research Guide
- Best Peptides for Anti-Aging & Longevity | Research Guide
- Best Peptides for Metabolic Health | Research Guide
- Best Peptides for Weight Management | Research Guide
- Best Peptides for Body Composition | Research Guide
- Best Peptides for Weight Loss | Research Guide
- Best Peptides for Cognitive Enhancement | Research Guide
- Retatrutide Dosing Guide | Protocols & Reconstitution
- Wound Healing Peptides | Research Compounds
- Muscle Growth Peptides | Research Compounds
- Immune Modulation Peptides | Research Compounds
Browse the research catalogue
Buying and verification
Frequently Asked Questions
Related Research
About the reviewer
Director of Research and Development, Volta Peptides
Marcus Hopkin, PhD, is Director of Research and Development at Volta Peptides. He has more than 12 years of analytical chemistry experience, including direct laboratory work in peptide synthesis, characterization, purity testing and stability assessment. His doctoral research at the University of Michigan examined novel peptide structures in the human proteome and their potential significance for therapeutic-peptide research. Before joining Volta Peptides he held research and development roles at Amgen and Eli Lilly and Company, and served as a lecturer at the University of Michigan.
Marcus reviewed this article for scientific and analytical accuracy on September 15, 2026. He did not write it. Technical review is internal review and is not peer review, independent third-party review or medical review.
Disclosure. Marcus Hopkin is an employee of Volta Peptides and serves as its Director of Research and Development. Volta Peptides sells research compounds related to subjects discussed in the content he writes and reviews. His reviews are internal scientific and technical review and must not be described as independent third-party review, peer review or medical review.